Oncology
Molecular Methodologies & Technologies
Susan Hsiao, MD, PhD
Associate Professor of Pathology and Cell Biology
Columbia University Irving Medical Center
New York, New York, United States
The 2018 CAP/IASLC/AMP Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors guideline is currently undergoing a revision and update. This revision process reviews published evidence since 2018 that may change the strength of existing guideline recommendations. It also expands the guideline, providing new recommendations to address new biomarkers and clinical scenarios. The 2024 draft recommendation statements have recently completed an international open public comment period. Project progress updates will be provided in this session, along with the opportunity to ask questions and provide feedback to Dr. Chitale (Expert Panelist, CAP/IASLC/AMP Lung Guideline Project representing AMP).
Learning Objectives:
1. Receive update on 2018 CAP/IASLC/AMP Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors guideline revision currently in progress.
2. Review results of open public comment period of the 2024 draft recommendation statements.
3. Provide feedback regarding new and emerging biomarkers to be addressed in the 2024 guideline.
Working Group Speaker: Dhananjay A. Chitale, MD, MBA (he/him/his) – Henry Ford Health